JP2000300663A - Selective separation membrane - Google Patents

Selective separation membrane

Info

Publication number
JP2000300663A
JP2000300663A JP11111227A JP11122799A JP2000300663A JP 2000300663 A JP2000300663 A JP 2000300663A JP 11111227 A JP11111227 A JP 11111227A JP 11122799 A JP11122799 A JP 11122799A JP 2000300663 A JP2000300663 A JP 2000300663A
Authority
JP
Japan
Prior art keywords
selective separation
separation membrane
membrane
polyvinylpyrrolidone
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11111227A
Other languages
Japanese (ja)
Inventor
Koyo Mabuchi
公洋 馬淵
Noriaki Kato
典昭 加藤
Motoki Kyo
基樹 京
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP11111227A priority Critical patent/JP2000300663A/en
Publication of JP2000300663A publication Critical patent/JP2000300663A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To substantially prevent the elution of a hydrophilic high polymer recognized as foreign matters within the living body by specifying the content of the hydrophobic high polymer to be extracted by prescribed % of an aqueous ethanol solution into a selective separation membrane consisting of the hydrophilic high polymer and a hydrophobic high polymer to a prescribed value or below per prescribed area of the liquid to the treated contact side membrane of the selective separation membrane. SOLUTION: The hydrophilic high polymer to be extracted by the 40% aqueous ethanol solution is <=10 mg per 1 m2 the area of liquid to be treated contact side membrane of the selective separation membrane. The selective separation membrane is adequately usable in applications where inconvenience is induced by the elution of the hydrophilic high polymer; for example, thickening, refining, etc., of food, beverages and physiologically active materials in addition a blood purification. The water to be treated includes food, beverages and physiologically active material- containing liquids, etc. If the selective separation membrane is applied to the blood purification application to return the water to be treated again to the human body, safety is improved and, therefore, the membrane is most effective when the blood or the component of the blood is used as the water to be treated.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、疎水性高分子と親
水性高分子からなる選択分離膜において、該親水性高分
子の溶出を抑え、安全性が向上した選択分離膜に関す
る。さらに詳細には、血液浄化に用いた際、親水性高分
子の血液への溶出を抑えることにより、安全性が向上し
た親水性高分子を含有する選択分離膜に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a selective separation membrane comprising a hydrophobic polymer and a hydrophilic polymer, in which the elution of the hydrophilic polymer is suppressed and safety is improved. More specifically, the present invention relates to a selective separation membrane containing a hydrophilic polymer with improved safety by suppressing elution of the hydrophilic polymer into blood when used for blood purification.

【0002】[0002]

【従来の技術】慢性腎不全患者の血液処理方法について
は、生体腎を模範とし、種々の膜性能向上技術、透析方
法が開発されてきた。それらに使用される膜素材として
はセルロース、セルロース誘導体などの天然素材とポリ
スルホン系、ポリメチルメタクリレート、ポリアクリロ
ニトリル、エチレンビニルアルコール共重合体などの合
成高分子素材が幅広く使用されている。合成高分子素材
の中では、生体適合性に優れ、尿毒症物質の高い除去性
能を発現しうるポリスルホン系樹脂が注目され、近年、
ポリスルホン系樹脂を用いた血液浄化用膜が多数上市さ
れている。ポリスルホン系樹脂は、熱可塑性の耐熱性エ
ンジニアプラスチックであり、各産業分野において幅広
く用途展開されている。
2. Description of the Related Art With regard to a method for treating blood of a patient with chronic renal failure, various techniques for improving membrane performance and dialysis methods have been developed, taking living kidney as an example. As the membrane material used for them, natural materials such as cellulose and cellulose derivatives and synthetic polymer materials such as polysulfone, polymethyl methacrylate, polyacrylonitrile, and ethylene vinyl alcohol copolymer are widely used. Among synthetic polymer materials, polysulfone-based resins that have excellent biocompatibility and can exhibit high removal performance of uremic substances have attracted attention.
Many blood purification membranes using polysulfone-based resins are on the market. Polysulfone resins are thermoplastic heat-resistant engineering plastics, and are widely used in various industrial fields.

【0003】ポリスルホン系樹脂は比較的疎水性が強
く、血液と接触した際に、血漿タンパク質を吸着しやす
い。このため血液浄化膜を作製する際に、血液との親和
性を高めるために、ポリスルホン系樹脂にポリビニルピ
ロリドンを混ぜることにより親水性を付与する方法が一
般的に用いられている。
[0003] Polysulfone resins are relatively hydrophobic and tend to adsorb plasma proteins when in contact with blood. For this reason, when fabricating a blood purification membrane, a method of imparting hydrophilicity by mixing polyvinylpyrrolidone with a polysulfone-based resin is generally used to increase affinity with blood.

【0004】親水性高分子、特にポリビニルピロリドン
を含む選択分離膜を用いた血液透析治療中に、ポリビニ
ルピロリドンの溶出に起因すると考えられるアナフィラ
キシーショック等の重篤な副作用が発生することが知ら
れている。また、ドイツにおいては、K−18(重量平
均分子量10000)以上のポリビニルピロリドンを静
注することはできないとの規制がある。さらに、ポリビ
ニルピロリドンを静注することによりアナフィラキシー
症状を示すことが報告されている(Pilar Maiques Asuer
o ら、The Annals of Pharmacotherapy, pp30, Janua
ry, Vol.30, 1996)。すなわち、ポリスルホン系樹脂膜
の親水化剤として、一般に用いられているポリビニルピ
ロリドンは安全性に問題があり、血液浄化用途に用いる
際には、血液へのポリビニルピロリドンの溶出をできる
限り抑える必要がある。
[0004] It is known that during hemodialysis treatment using a selective separation membrane containing a hydrophilic polymer, particularly polyvinylpyrrolidone, serious side effects such as anaphylactic shock caused by elution of polyvinylpyrrolidone occur. I have. Further, in Germany, there is a regulation that polyvinylpyrrolidone having K-18 (weight average molecular weight of 10,000) or more cannot be injected intravenously. In addition, it has been reported that intravenous injection of polyvinylpyrrolidone causes anaphylactic symptoms (Pilar Maiques Asuer
o et al., The Annals of Pharmacotherapy, pp30, Janua
ry, Vol.30, 1996). That is, polyvinylpyrrolidone, which is generally used as a hydrophilizing agent for a polysulfone-based resin membrane, has a problem in safety, and when used for blood purification, it is necessary to suppress the dissolution of polyvinylpyrrolidone into blood as much as possible. .

【0005】ポリビニルピロリドンの溶出を抑えるため
に、これまで多くの方法が提案されている。例えば、特
開平10−230148には、ポリビニルピロリドンを
含むポリスルホン系中空糸膜を熱処理あるいは放射線処
理を施すことにより、ポリビニルピロリドンを架橋し、
不溶化することでポリビニルピロリドンの溶出を抑える
方法が開示されている。また、特開平10−24399
9には、選択分離層の厚みを適切にすることで、ポリビ
ニルピロリドンの溶出を抑える方法が開示されている。
しかしながら、これらの手法は、水あるいは熱水への溶
出量抑制に対しては効果があるものの、後述するよう
に、血液あるいは血漿への溶出量の指標となる40%エ
タノール水溶液への溶出量抑制には不十分である。実
際、ポリビニルピロリドンの溶出量を抑制したといわれ
る透析膜においても、未だ、アナフィラキシーショック
発生の報告があり(例えば、中山ら、O-439 、第43回日
本透析医学会予稿集、pp620 、 1998 )、ポリビニルピ
ロリドンを含有する選択分離膜の安全性に対する問題は
解決していないのが現状である。
[0005] In order to suppress the elution of polyvinylpyrrolidone, many methods have been proposed so far. For example, JP-A-10-230148 discloses that a polysulfone-based hollow fiber membrane containing polyvinylpyrrolidone is subjected to heat treatment or radiation treatment to crosslink polyvinylpyrrolidone,
A method for suppressing the elution of polyvinylpyrrolidone by insolubilization is disclosed. Also, JP-A-10-24399
No. 9 discloses a method for suppressing the elution of polyvinylpyrrolidone by making the thickness of the selective separation layer appropriate.
However, although these techniques are effective in suppressing the amount of elution into water or hot water, as described later, the amount of elution into 40% ethanol aqueous solution, which is an indicator of the amount of elution into blood or plasma, is described below. Is not enough. In fact, there is still a report of the occurrence of anaphylactic shock in dialysis membranes that are said to suppress the amount of polyvinylpyrrolidone eluted (eg, Nakayama et al., O-439, 43rd Annual Meeting of the Japanese Society for Dialysis Therapy, pp620, 1998). At present, the problem on the safety of the selective separation membrane containing polyvinylpyrrolidone has not been solved.

【0006】[0006]

【発明が解決しようとする課題】本発明は、上記課題を
解決することを目的とし、生体内において異物と認識さ
れる親水性高分子が溶出しにくい選択分離膜を提供する
ことを目的とする。
SUMMARY OF THE INVENTION An object of the present invention is to solve the above-mentioned problems and to provide a selective separation membrane in which a hydrophilic polymer which is recognized as a foreign substance in a living body is hardly eluted. .

【0007】[0007]

【課題を解決するための手段】本研究者らは、上記課題
を解決し、優れた安全性を具備する選択分離膜を提供す
るため鋭意研究した結果、本発明に到達した。すなわち
本発明は、以下のものである。 疎水性高分子と親水性高分子からなる選択分離膜に
おいて、40% エタノール水溶液で抽出される該親水性高
分子が選択分離膜の被処理液接触側膜面積1m2 あたり10
mg以下であることを特徴とする選択分離膜。 被処理液が血液である上記記載の選択分離膜。 血液透析用、血液透析濾過用、血液濾過用、血漿分
離用、血漿分画用または腹水濃縮用に用いる上記また
は記載の選択分離膜。 選択分離膜が中空糸膜である上記乃至記載の選
択分離膜。 疎水性高分子がポリスルホン系樹脂である上記乃
至記載の選択分離膜。 親水性高分子がポリビニルピロリドンである上記
乃至記載の選択分離膜。
Means for Solving the Problems The present inventors have made intensive studies to solve the above-mentioned problems and to provide a selective separation membrane having excellent safety, and as a result, have reached the present invention. That is, the present invention is as follows. In selective separation membrane comprising a hydrophobic polymer and a hydrophilic polymer, the liquid to be treated contact side film of the hydrophilic polymer selected separation membranes are extracted with 40% aqueous ethanol area 1 m 2 per 10
A selective separation membrane characterized in that the amount is not more than mg. The selective separation membrane according to the above, wherein the liquid to be treated is blood. The selective separation membrane described above or described for use in hemodialysis, hemodiafiltration, hemofiltration, plasma separation, plasma fractionation, or ascites concentration. The selective separation membrane according to any of the above-mentioned or the above, wherein the selective separation membrane is a hollow fiber membrane. 4. The selective separation membrane according to any one of the above items, wherein the hydrophobic polymer is a polysulfone resin. 4. The selective separation membrane according to any one of the above, wherein the hydrophilic polymer is polyvinylpyrrolidone.

【0008】本発明において、40%エタノール水溶液
で抽出される親水性高分子が、選択分離膜の被処理液側
膜面積1m2 あたり10mg以下であるのは、次の理由
による。まず、疎水性高分子と親水性高分子からなる選
択分離膜において、該親水性高分子の溶出を皆無にする
ことは不可能であるので安全性の上限を決める必要があ
った。溶出するポリビニルピロリドンに対する、アレル
ギー反応は人によって異なるが、我々がビーグル犬を用
いてポリビニルピロリドンを静注したときのアナフィラ
キシー反応を調べたところ、体重1Kg当たり5mgの
ポリビニルピロリドンの静注まではアナフィラキシー反
応を起こさないことがわかった。人の固体差を加味しビ
ーグル犬の安全投与量の1/10を上限とし、また通常
血液透析に用いられる透析器の膜面積の上限が約2m2
であること、透析患者の体重の下限を40kgとする
と、1透析当たり20mgがポリビニルピロリドンの投
与上限であり、1m2 当たり10mg以下とすることで
安全性が確保できると考えられる。
In the present invention, the reason why the amount of the hydrophilic polymer extracted with a 40% aqueous ethanol solution is 10 mg or less per 1 m 2 of the membrane area of the liquid to be treated of the selective separation membrane is as follows. First, in a selective separation membrane composed of a hydrophobic polymer and a hydrophilic polymer, it is impossible to completely eliminate the elution of the hydrophilic polymer, so it was necessary to determine the upper limit of safety. The allergic reaction to the eluted polyvinylpyrrolidone varies from person to person, but when we examined the anaphylactic reaction of polyvinylpyrrolidone intravenously using beagle dogs, the anaphylactic reaction was observed until the intravenous injection of 5 mg polyvinylpyrrolidone per kg body weight. Did not occur. Taking into account individual differences, the upper limit is 1/10 of the safe dose of a beagle dog, and the upper limit of the membrane area of a dialyzer usually used for hemodialysis is about 2 m 2.
If the lower limit of the weight of a dialysis patient is 40 kg, 20 mg per dialysis is the upper limit of administration of polyvinylpyrrolidone, and it is considered that safety can be ensured by setting it to 10 mg or less per 1 m 2 .

【0009】実際、我々が現在市販されているポリビニ
ルピロリドンを含有するポリスルホン系透析膜の40%
エタノール水溶液での抽出試験によるポリビニルピロリ
ドンの溶出量を測定したところ、1m2 あたり数十mg
〜数百mgの溶出があることがわかった。そのため、ポ
リビニルピロリドンを含有するポリスルホン系膜の安全
性を確保するためには、これらの事実により1m2 当た
り10mg以下の溶出量に抑えることで達成できる。
In fact, we have found that 40% of the polysulfone-based dialysis membranes currently containing polyvinylpyrrolidone are commercially available.
When the elution amount of polyvinylpyrrolidone was measured by an extraction test with an aqueous ethanol solution, several tens mg per 1 m 2 was measured.
It was found that there was ~ 100 mg of elution. Therefore, in order to ensure the safety of polysulfone film containing polyvinylpyrrolidone it can be achieved by suppressing the elution amount of less 1 m 2 per 10mg These facts.

【0010】また、我々が40%エタノール水溶液によ
る抽出を選択した理由は以下による。すなわち、血液浄
化の目的で選択分離膜を使用する場合、被処理液は水で
はなく、血液あるいは血漿である。血液あるいは血漿
は、水に電解質や血漿タンパク質、血球、その他の有機
成分を含むので、各種溶質に対する溶解力は水や熱水に
比べかなり高いといわれている。40%エタノール水溶
液による抽出は、血液回路に用いられる塩化ビニルの添
加剤(フタル酸エステル)の抽出量の測定に使用され、
水や熱水に比べ、より血液に近い抽出力を持つといわれ
ている。この40%エタノール水溶液を用いることによ
ってポリビニルピロリドンを含有する選択分離膜の血液
接触時のポリビニルピロリドンの溶出量を測定できると
考えた。
The reason why we chose extraction with a 40% aqueous ethanol solution is as follows. That is, when a selective separation membrane is used for the purpose of blood purification, the liquid to be treated is not blood but blood or plasma. Blood or plasma is said to have much higher solubility for various solutes than water or hot water because water contains electrolytes, plasma proteins, blood cells, and other organic components. Extraction with a 40% aqueous ethanol solution is used to measure the amount of vinyl chloride additive (phthalate ester) used in the blood circuit,
Compared to water and hot water, it is said to have an extraction power closer to blood. It was thought that the amount of polyvinylpyrrolidone eluted when the selective separation membrane containing polyvinylpyrrolidone was brought into contact with blood could be measured by using this 40% ethanol aqueous solution.

【0011】実際、我々が現在、市販されている、ポリ
ビニルピロリドンを含有する選択分離膜のポリビニルピ
ロリドン溶出量を他の条件は同一として、70℃純水と
40%エタノール水溶液で比較したところ、40%エタ
ノール水溶液による抽出量は70℃純水の抽出量の5〜
20倍となることがわかった。
In fact, when we compared the amount of polyvinylpyrrolidone eluted from a commercially available selective separation membrane containing polyvinylpyrrolidone under the same other conditions with pure water at 70 ° C. and a 40% aqueous ethanol solution, we found that 40 % Ethanol aqueous solution extraction volume is 5-5 of 70 ° C pure water extraction volume.
It turned out to be 20 times.

【0012】以上の研究により、40%エタノール水溶
液で抽出される該親水性高分子が、該選択分離膜の被処
理液側膜面積1m2 当たり10mg以下にすることによ
り、安全性が著しく向上した選択分離膜が得られること
を見出し、本発明に到達した。
According to the above research, the safety was remarkably improved by reducing the amount of the hydrophilic polymer extracted with a 40% aqueous ethanol solution to 10 mg or less per 1 m 2 of the membrane area of the selective separation membrane on the side of the liquid to be treated. The inventors have found that a selective separation membrane can be obtained, and have reached the present invention.

【0013】本発明において、被処理液とは、選択分離
膜によって分離対象となる液体をいい、被処理液接触側
とは、膜の被処理液が接触する側の表面をいう。すなわ
ち、血液透析や血液濾過、血液透析濾過、血漿分離にお
いては、被処理液は血液であり,血漿分画においては被
処理液は血漿であり、この場合被処理液接触側とは、膜
の血液(血漿分画の場合は血漿)接触面をいう。中空糸
形状の選択分離膜を血液浄化用途に用いた場合、被処理
液接触側とは通常、中空糸内側である。血液透析や血液
透析濾過においては、膜の片側に血液を、反対側に透析
液を流すが、膜から被処理液へ親水性高分子の溶出を抑
えることにより安全性を向上する目的から明らかなよう
に、このような場合、本発明において被処理液は血液あ
るいは血液成分であって、透析液ではない。
In the present invention, the liquid to be treated refers to the liquid to be separated by the selective separation membrane, and the liquid contacting side refers to the surface of the membrane on the side in contact with the liquid to be treated. That is, in hemodialysis, hemofiltration, hemodiafiltration, and plasma separation, the liquid to be treated is blood, and in the plasma fraction, the liquid to be treated is plasma. Refers to the blood (plasma in the case of plasma fraction) contact surface. When the hollow fiber-shaped selective separation membrane is used for blood purification, the contact side of the liquid to be treated is usually the inside of the hollow fiber. In hemodialysis and hemodiafiltration, blood flows on one side of the membrane and dialysate flows on the other side, but it is clear from the purpose of improving safety by suppressing elution of hydrophilic polymers from the membrane to the liquid to be treated. As described above, in such a case, the liquid to be treated in the present invention is blood or a blood component, not a dialysate.

【0014】また、本発明は、血液浄化の他、親水性高
分子が溶出することで不都合が生じる用途、例えば、食
品や飲料、生理活性物質の濃縮や精製等に好適に利用で
き、被処理液としては食品、飲料、生理活性物質含有液
体等を挙げることができるが、被処理液を再び人体に戻
す血液浄化用途に本発明を応用すれば、安全性が向上す
るため、血液あるいは血液の成分を被処理液として用い
た場合に、本発明は最も効果的である。本発明の選択分
離膜は、上述のように処理後の血液を人体に戻す血液浄
化用途に応用することが好ましく、具体的には血液透析
膜、血液透析濾過膜、血液濾過膜、血漿分離膜、血漿分
画膜、腹水濃縮膜などが挙げらる。本発明の選択分離膜
のとりうる形態としては、平膜、管状膜、中空糸膜等が
挙げられるが、単位容積あたりの膜面積を大きくとれる
中空糸膜が好ましい。
In addition, the present invention can be suitably used for blood purification and other applications in which inconvenience is caused by elution of a hydrophilic polymer, for example, concentration and purification of foods and beverages, and physiologically active substances. Examples of the liquid include foods, beverages, physiologically active substance-containing liquids, and the like. However, if the present invention is applied to a blood purification application in which the liquid to be treated is returned to the human body again, the safety is improved, so that blood or blood The present invention is most effective when the components are used as the liquid to be treated. The selective separation membrane of the present invention is preferably applied to a blood purification application for returning blood after treatment to the human body as described above, and specifically, a hemodialysis membrane, a hemodiafiltration membrane, a blood filtration membrane, and a plasma separation membrane. , A plasma fractionation membrane, an ascites concentration membrane, and the like. Possible forms of the selective separation membrane of the present invention include a flat membrane, a tubular membrane, a hollow fiber membrane and the like, and a hollow fiber membrane capable of increasing a membrane area per unit volume is preferable.

【0015】本発明における疎水性高分子とはポリエス
テル、ポリカーボネート、ポリウレタン、ポリアミド、
ポリスルホン、ポリエーテルスルホン、ポリメチルメタ
クリレートなどの合成高分子やセルローストリアセテー
ト、セルロースナイトレート等のセルロース系素材があ
り、特に限定されるものではないが、ポリスルホン、ポ
リエーテルスルホン等のポリスルホン系素材は、血液浄
化に用いた際,生体適合性に優れ、尿毒症物質の高い除
去性能が得られるので好ましい。また、これらは単独で
用いても2種以上を混合して用いても良い。
In the present invention, the hydrophobic polymer includes polyester, polycarbonate, polyurethane, polyamide,
Polysulfone, polyethersulfone, synthetic polymers such as polymethyl methacrylate and cellulose-based materials such as cellulose triacetate and cellulose nitrate include, but are not particularly limited to, polysulfone-based materials such as polysulfone and polyethersulfone, When used for blood purification, it is preferable because it has excellent biocompatibility and high removal performance of uremic substances. These may be used alone or as a mixture of two or more.

【0016】本発明における親水性高分子とはポリエチ
レングリコール、ポリビニルアルコール、ポリビニルピ
ロリドン、カルボキシメチルセルロース、デンプンおよ
びその誘導体、酢酸セルロースなどの素材であるが、ポ
リスルホン系樹脂との相溶性を有することから好ましい
のはポリビニルピロリドンである。
The hydrophilic polymer in the present invention is a material such as polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose, starch and its derivatives, and cellulose acetate, and is preferable because of its compatibility with polysulfone resin. Is polyvinylpyrrolidone.

【0017】本発明の実施形態としては、親水性高分子
の分子量が最も重要である。ポリスルホン系樹脂とポリ
ビニルピロリドンからなる膜において、ポリビニルピロ
リドンは、ポリスルホン系樹脂に取り囲まれて存在して
いると考えられる。そのため、親水性高分子の分子量を
大きくすることで、膜中から抜け落ちにくくなる。ポリ
ビニルピロリドンは分子量の異なるグレードが市販され
ており、最も分子量が大きいグレード(K-90)は、数平
均分子量が約36万程度であり、この程度の分子量のポ
リビニルピロリドンは、膜中から抜け落ちることは考え
にくい。しかし、市販のポリビニルピロリドン分子量分
布を有しており、分子量数万〜10万程度の分子が多量に
含まれている。われわれの検討結果では、K-90を使用し
て作製されたポリスルホン系樹脂膜の40%エタノール
水溶液での抽出実験により、溶出してくるポリビニルピ
ロリドンをゲルパーミエーションクロマトグラフィーに
て測定したところ、その分子量は2〜5万程度であり、
10万以上の分子量のポリビニルピロリドンはほとんど検
出されなかった。すなわち、クロマトグラフ法や再沈殿
法など方法は問わないが、市販のポリビニルピロリドン
K-90に処置を施し、低分子量体を積極的に除去し、これ
を中空糸膜製膜する際に使用することによって、40%
エタノール水溶液抽出によるポリビニルピロリドンの溶
出を、被処理液接触側膜面積1m2あたり10mg以下に抑え
ることが可能になる。除去される低分子量体は通常分子
量5万未満、好ましくは10万未満である。
In the embodiment of the present invention, the molecular weight of the hydrophilic polymer is most important. In the film composed of the polysulfone-based resin and polyvinylpyrrolidone, it is considered that polyvinylpyrrolidone is present surrounded by the polysulfone-based resin. For this reason, by increasing the molecular weight of the hydrophilic polymer, it becomes difficult for the hydrophilic polymer to fall out of the film. Polyvinylpyrrolidone is commercially available in grades with different molecular weights. The grade with the highest molecular weight (K-90) has a number average molecular weight of about 360,000, and polyvinylpyrrolidone with this molecular weight falls out of the film. Is hard to imagine. However, it has a commercially available molecular weight distribution of polyvinylpyrrolidone, and contains a large amount of molecules having a molecular weight of about tens of thousands to 100,000. According to our study results, the eluted polyvinylpyrrolidone was measured by gel permeation chromatography in an extraction experiment with a 40% aqueous ethanol solution of a polysulfone-based resin membrane prepared using K-90. The molecular weight is about 20,000 to 50,000,
Polyvinylpyrrolidone having a molecular weight of 100,000 or more was hardly detected. That is, any method such as chromatographic method and reprecipitation method can be used, but commercially available polyvinylpyrrolidone
By treating K-90 to positively remove low molecular weight substances and using this in forming hollow fiber membranes, 40%
Elution of polyvinylpyrrolidone by extraction with an aqueous ethanol solution can be suppressed to 10 mg or less per 1 m 2 of the membrane area on the liquid side to be treated. The low molecular weight substance to be removed usually has a molecular weight of less than 50,000, preferably less than 100,000.

【0018】以下実施例により本発明の詳細を示す。Hereinafter, the present invention will be described in detail with reference to examples.

【0019】40%エタノール抽出試験は以下のような
手順で行った。中空糸膜モジュールの中空糸内側(被処
理液側)に400mLの純水を流してフラッシング作業
を行った後、モジュール内の純水を40vol %エタノー
ル水溶液で中空糸内側を置換した。中空糸外側のモジュ
ールケース内も40vol %エタノールで満たして封止し
た。次に200mLの40vol %エタノール水溶液を、
流量150mL/min、40℃、1時間中空糸内側を
循環させた後、循環した40vol %エタノール水溶液中
のポリビニルピロリドン濃度を測定した。モジュールの
中空糸内側容積とモジュール入口出口のヘッダー部分の
体積、すなわちプライミングボリュームに200mL を
加えた、抽出液総体積と抽出液中のポリビニルピロリド
ン濃度から、抽出されたポリビニルピロリドン重量を求
め、さらに、中空糸膜モジュールの膜面積(中空糸内径
基準)から、被処理液接触側膜面積1m2あたりのポリビ
ニルピロリドン抽出量を求める。
The 40% ethanol extraction test was performed according to the following procedure. After flushing was performed by flowing 400 mL of pure water inside the hollow fiber (the liquid to be treated) of the hollow fiber membrane module, the inside of the hollow fiber was replaced with 40 vol% ethanol aqueous solution of the pure water in the module. The inside of the module case outside the hollow fiber was also filled with 40 vol% ethanol and sealed. Next, 200 mL of 40 vol% ethanol aqueous solution
After circulating the inside of the hollow fiber at a flow rate of 150 mL / min at 40 ° C. for 1 hour, the concentration of polyvinylpyrrolidone in the circulated 40 vol% ethanol aqueous solution was measured. The weight of the extracted polyvinylpyrrolidone was determined from the total volume of the extract and the concentration of polyvinylpyrrolidone in the extract obtained by adding 200 mL to the hollow fiber inner volume of the module and the header portion at the module inlet / outlet, that is, the priming volume. From the membrane area of the hollow fiber membrane module (based on the inner diameter of the hollow fiber), the amount of polyvinylpyrrolidone extracted per 1 m 2 of the membrane area on the liquid side to be treated is determined.

【0020】ポリビニルピロリドンの濃度測定にはK.Mu
eller (1968)の方法を用いた。すなわち、検体に
クエン酸とヨウ素液を加え、吸光度を測定し、ポリビニ
ルピロリドンK-90から求めた検量線により濃度を求め
た。ここで濃度測定の際、エタノールによる発色の阻害
をなくすため2倍以上に希釈する必要がある。具体的に
は例えば2倍希釈であれば、検体(標品あるいは抽出
液)を1.25mL、水1.25mL、0.2Mクエン
酸水溶液1.25mL、0.006Nヨウ素水溶液0.
5mLをよく混合し、10分静置した後、470nmで
の吸光度を測定し、ポリビニルピロリドンの濃度を測定
した。
For measuring the concentration of polyvinylpyrrolidone, use K.Mu
eller (1968). That is, citric acid and an iodine solution were added to the sample, the absorbance was measured, and the concentration was determined by a calibration curve determined from polyvinylpyrrolidone K-90. Here, at the time of concentration measurement, it is necessary to dilute at least two times in order to eliminate the inhibition of color development by ethanol. Specifically, for example, in the case of a 2-fold dilution, 1.25 mL of a sample (a sample or an extract), 1.25 mL of water, 1.25 mL of a 0.2 M aqueous citric acid solution, and 1.25 mL of a 0.006 N iodine aqueous solution.
After 5 mL was mixed well and allowed to stand for 10 minutes, the absorbance at 470 nm was measured, and the concentration of polyvinylpyrrolidone was measured.

【0021】[0021]

【実施例】【Example】

【0022】実施例1 ポリビニルピロリドン(K−90,BASF社製)0.025g/m
L の水溶液を、水溶液の水に対する浴比が2.5 〜3.0 倍
の貧溶媒であるアセトン中へ滴下し、再沈殿法により積
極的に低分子量体を除去したポリビニルピロリドンを収
率90% で得た。これを以下、精製ポリビニルピロリドン
と称する。精製前のポリビニルピロリドンと、精製時に
排除した分画のゲルパーミエーションクロマトグラフィ
ーのプロファイルを図1、図2に示す。図より明らかな
ように、精製時に低分子分画(透過時間が長い方向)の
みが選択的に排除されていることがわかる。ポリエーテ
ルスルホン(4800P、住友化学社製)16重量部と
精製ポリビニルピロリドン5重量部をジメチルアセトア
ミド74重量部、水5重量部を混合溶解、脱泡した紡糸
原液として、50%ジメチルアセトアミド水溶液を芯液
として使用し、これを二重管オリフィスより吐出し、5
0cmの空走部を経て、75℃、水の凝固浴中に導き中
空糸膜を形成し、水洗後まきとり、60℃で20hr乾
燥した。この中空糸膜を使用して中空糸内径基準膜面積
1.5m2のモジュールを得た。このモジュールで40%
エタノール抽出試験を行った結果、ポリビニルピロリド
ンの溶出は中空糸内膜面積1m2 あたり1.0mgであっ
た。
Example 1 Polyvinylpyrrolidone (K-90, manufactured by BASF) 0.025 g / m
The aqueous solution of L was dropped into acetone, a poor solvent having a bath ratio of 2.5 to 3.0 times that of the aqueous solution, to obtain polyvinylpyrrolidone in a yield of 90% from which low-molecular-weight substances were positively removed by the reprecipitation method. . This is hereinafter referred to as purified polyvinylpyrrolidone. FIGS. 1 and 2 show the profiles of polyvinylpyrrolidone before purification and the fraction excluded during purification by gel permeation chromatography. As is clear from the figure, it can be seen that only the low molecular fraction (in the direction of longer permeation time) was selectively excluded during purification. A mixture of 16 parts by weight of polyether sulfone (4800P, manufactured by Sumitomo Chemical Co., Ltd.), 5 parts by weight of purified polyvinylpyrrolidone, 74 parts by weight of dimethylacetamide and 5 parts by weight of water was dissolved and defoamed. Liquid and discharge it from the double pipe orifice.
A hollow fiber membrane was formed at 75 ° C. in a coagulation bath of water through a free running section of 0 cm, washed with water, washed, and dried at 60 ° C. for 20 hours. Using this hollow fiber membrane, a module having a hollow fiber inner diameter reference membrane area of 1.5 m 2 was obtained. 40% with this module
Result of the ethanol extraction test, elution of polyvinylpyrrolidone were hollow fiber within the membrane area 1 m 2 per 1.0 mg.

【0023】実施例2 ポリスルホン(P−1700、AMOCO社製)20重
量部、精製ポリビニルピロリドン6重量部、ジメチルア
セトアミド74重量部を混合溶解、脱泡した紡糸原液と
して、45%ジメチルアセトアミド水溶液を芯液として
使用し、これを二重管オリフィスより吐出し、70cm
の空走部を経て、50℃、水の凝固浴中に導き中空糸膜
を形成し、水洗後まきとり、60℃で20hr乾燥し
た。この中空糸を使用して中空糸内径基準膜面積1.5
m2のモジュールを得た。このモジュールで40%エタノ
ール抽出試験を行った結果、ポリビニルピロリドンの溶
出は中空糸内膜面積1m2 あたり1.3mgであった。
Example 2 20 parts by weight of polysulfone (P-1700, manufactured by AMOCO), 6 parts by weight of purified polyvinylpyrrolidone and 74 parts by weight of dimethylacetamide were mixed and dissolved, and a 45% aqueous solution of dimethylacetamide was used as a defoaming spinning solution. Used as a liquid and discharged from the double pipe orifice, 70 cm
The hollow fiber membrane was formed at 50 ° C. in a coagulation bath of water, washed, washed with water, and dried at 60 ° C. for 20 hours. By using this hollow fiber, the inner diameter of the hollow fiber is 1.5
m 2 modules were obtained. 40% ethanol extraction test The result of this module, the elution of polyvinylpyrrolidone were hollow fiber within the membrane area 1 m 2 per 1.3 mg.

【0024】比較例 ポリビニルピロリドンとして精製していないK−90
(BASF社製)を用いた以外は実施例2と同様に、中空糸
膜を紡糸し、得られた中空糸を使用して中空糸内径基準
膜面積1.5m2のモジュールを得た。このモジュールで
40%エタノール抽出試験を行った結果、ポリビニルピ
ロリドンの溶出は中空糸内膜面積1m2 あたり15.2m
gであった。
Comparative Example K-90 not purified as polyvinylpyrrolidone
A hollow fiber membrane was spun in the same manner as in Example 2 except that (manufactured by BASF) was used, and a module having a hollow fiber inner diameter reference membrane area of 1.5 m 2 was obtained using the obtained hollow fiber. As a result of conducting a 40% ethanol extraction test with this module, the dissolution of polyvinylpyrrolidone was 15.2 m per 1 m 2 of hollow fiber inner membrane area.
g.

【0025】[0025]

【表1】 [Table 1]

【0026】[0026]

【発明の効果】本発明により、親水性高分子を含有する
が、該親水性高分子の溶出が少ない選択分離膜を提供す
ることができた。
According to the present invention, it is possible to provide a selective separation membrane which contains a hydrophilic polymer but has little elution of the hydrophilic polymer.

【図面の簡単な説明】[Brief description of the drawings]

【図1】ポリビニルピロリドン(K−90)のゲルパー
ミエーションクロマトグラフィーのプロファイルを示
す。
FIG. 1 shows the profile of gel permeation chromatography of polyvinylpyrrolidone (K-90).

【図2】ポリビニルピロリドン精製時に排除した分画の
ゲルパーミエーションクロマトグラフィーのプロファイ
ルを示す。
FIG. 2 shows a gel permeation chromatography profile of a fraction excluded during purification of polyvinylpyrrolidone.

【図3】40%エタノール抽出により溶出が検出された
ポリビニルピロリドンのゲルパーミエーションクロマト
グラフィーのプロファイルを示す。
FIG. 3 shows a gel permeation chromatography profile of polyvinylpyrrolidone in which elution was detected by 40% ethanol extraction.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) B01D 71/68 B01D 71/68 Fターム(参考) 4C077 AA05 AA09 AA20 BB01 BB02 KK30 LL05 LL12 NN03 NN04 PP15 PP18 PP27 4D006 GA13 HA02 MA01 MB20 MC10 MC16 MC18 MC19 MC32 MC33 MC37 MC40X MC48 MC49 MC53 MC54 MC62X MC63X MC88 NA04 NA64 PB09 PB42 PC47 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (Reference) B01D 71/68 B01D 71/68 F-term (Reference) 4C077 AA05 AA09 AA20 BB01 BB02 KK30 LL05 LL12 NN03 NN04 PP15 PP18 PP27 4D006 GA13 HA02 MA01 MB20 MC10 MC16 MC18 MC19 MC32 MC33 MC37 MC40X MC48 MC49 MC53 MC54 MC62X MC63X MC88 NA04 NA64 PB09 PB42 PC47

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 疎水性高分子と親水性高分子からなる選
択分離膜において、40% エタノール水溶液で抽出される
該親水性高分子が選択分離膜の被処理液接触側膜面積1m
2 あたり10mg以下であることを特徴とする選択分離膜。
1. A selective separation membrane comprising a hydrophobic polymer and a hydrophilic polymer, wherein the hydrophilic polymer extracted with a 40% aqueous ethanol solution has a membrane area of 1 m on the side of the selective separation membrane contacting the liquid to be treated.
A selective separation membrane characterized by being 10 mg or less per 2 .
【請求項2】 被処理液が血液である請求項1記載の選
択分離膜。
2. The selective separation membrane according to claim 1, wherein the liquid to be treated is blood.
【請求項3】 血液透析用、血液透析濾過用、血液濾過
用、血漿分離用、血漿分画用または腹水濃縮用に用いる
請求項1または2記載の選択分離膜。
3. The selective separation membrane according to claim 1, which is used for hemodialysis, hemodiafiltration, hemofiltration, plasma separation, plasma fractionation, or ascites concentration.
【請求項4】 選択分離膜が中空糸膜である請求項1乃
至3記載の選択分離膜。
4. The selective separation membrane according to claim 1, wherein the selective separation membrane is a hollow fiber membrane.
【請求項5】 疎水性高分子がポリスルホン系樹脂であ
る請求項1乃至4記載の選択分離膜。
5. The selective separation membrane according to claim 1, wherein the hydrophobic polymer is a polysulfone resin.
【請求項6】親水性高分子がポリビニルピロリドンであ
る請求項1乃至5記載の選択分離膜。
6. The selective separation membrane according to claim 1, wherein the hydrophilic polymer is polyvinylpyrrolidone.
JP11111227A 1999-04-19 1999-04-19 Selective separation membrane Pending JP2000300663A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11111227A JP2000300663A (en) 1999-04-19 1999-04-19 Selective separation membrane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11111227A JP2000300663A (en) 1999-04-19 1999-04-19 Selective separation membrane

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006309864A Division JP4582081B2 (en) 2006-11-16 2006-11-16 Selective separation membrane for blood treatment, manufacturing method and module thereof

Publications (1)

Publication Number Publication Date
JP2000300663A true JP2000300663A (en) 2000-10-31

Family

ID=14555781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11111227A Pending JP2000300663A (en) 1999-04-19 1999-04-19 Selective separation membrane

Country Status (1)

Country Link
JP (1) JP2000300663A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009926A1 (en) * 2001-07-24 2003-02-06 Asahi Medical Co., Ltd. Hollow fiber membrane for purifying blood
JP2004305561A (en) * 2003-04-09 2004-11-04 Toyobo Co Ltd Hollow yarn type blood purification membrane
WO2005089918A1 (en) * 2004-03-23 2005-09-29 Toyo Boseki Kabushiki Kaisha Polysulfone-base permselective hollow fiber membrane bundle and process for producing the same
JP2006230458A (en) * 2005-02-22 2006-09-07 Toyobo Co Ltd Polysulfone-based permselective hollow fiber membrane bundle and blood purifier
US7922007B2 (en) 2004-03-22 2011-04-12 Toyo Boseki Kabushiki Kaisha Separation membrane with selective permeability and process for producing the same
CN114733369A (en) * 2022-05-09 2022-07-12 苏州君康医疗科技有限公司 Plasma separation membrane and production method of plasma component separation membrane

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009926A1 (en) * 2001-07-24 2003-02-06 Asahi Medical Co., Ltd. Hollow fiber membrane for purifying blood
KR100829692B1 (en) * 2001-07-24 2008-05-16 아사히 카세이 쿠라레 메디칼 가부시키가이샤 Hollow Fiber Membrane for Purifying Blood
JP2004305561A (en) * 2003-04-09 2004-11-04 Toyobo Co Ltd Hollow yarn type blood purification membrane
US7922007B2 (en) 2004-03-22 2011-04-12 Toyo Boseki Kabushiki Kaisha Separation membrane with selective permeability and process for producing the same
WO2005089918A1 (en) * 2004-03-23 2005-09-29 Toyo Boseki Kabushiki Kaisha Polysulfone-base permselective hollow fiber membrane bundle and process for producing the same
JP2006230458A (en) * 2005-02-22 2006-09-07 Toyobo Co Ltd Polysulfone-based permselective hollow fiber membrane bundle and blood purifier
CN114733369A (en) * 2022-05-09 2022-07-12 苏州君康医疗科技有限公司 Plasma separation membrane and production method of plasma component separation membrane

Similar Documents

Publication Publication Date Title
US10265453B2 (en) Liver support system
JP4211168B2 (en) Dialyzer manufacturing method and sterilization method
US5496637A (en) High efficiency removal of low density lipoprotein-cholesterol from whole blood
EP0488095B1 (en) High efficiency removal of low density lipoprotein-cholesterol from whole blood
US9138529B2 (en) Anticoagulant-free dialysis systems and methods
US5418061A (en) Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
JP4190079B2 (en) Hollow fiber membrane for blood purification and hollow fiber membrane artificial kidney
EP3279227A1 (en) Copolymer and medical device using same, separation membrane module for medical use, and blood purifier
JP4061798B2 (en) Semipermeable membrane for blood treatment and dialyzer for blood treatment using the same
EP3495398B1 (en) Copolymer, as well as separation membrane, medical device, and blood purifier in which said copolymer is used
WO2009040123A1 (en) Hydrophilic membranes with a non-ionic surfactant
JP3966481B2 (en) Semipermeable membrane
JP2000300663A (en) Selective separation membrane
JP2000296318A (en) Polysulfone-base blood treatment module
US6632359B1 (en) Blood purifying apparatus
JP4582081B2 (en) Selective separation membrane for blood treatment, manufacturing method and module thereof
EP3520886A1 (en) Separation membrane module
EP0570232A2 (en) Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
JP5062773B2 (en) Blood purifier
JP2003290638A (en) Polysulfone-based semipermeable membrane and artificial kidney using the same
JP4810720B2 (en) Selective removal membrane and blood processor using the same
JP3489372B2 (en) Perm-selective separation membrane
JP2009078121A (en) Blood purifier and its production method
JP4381022B2 (en) Hollow fiber blood purification membrane
JPH0970526A (en) Permselective separation membrane

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051208

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061019

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061109

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061116

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20061222

A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070309

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202